Detalhe da pesquisa
1.
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Am J Hematol
; 99(2): 254-262, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38108611
2.
Stenotrophomonas maltophilia Infections in Haematological Malignancies and Hematopoietic Stem Cell Transplantation: A Case Series including Cefiderocol-Based Regimens.
Medicina (Kaunas)
; 60(1)2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38256349
3.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354090
4.
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia.
Eur J Haematol
; 110(4): 354-361, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480004
5.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
6.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
7.
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Int J Mol Sci
; 23(14)2022 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35886899
8.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739457
9.
Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists.
Int J Mol Sci
; 22(5)2021 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33802366
10.
Precision Medicine in Systemic Mastocytosis.
Medicina (Kaunas)
; 57(11)2021 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34833353
11.
Atypical Chronic Myeloid Leukemia: Where Are We Now?
Int J Mol Sci
; 21(18)2020 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32962122
12.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461
13.
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 182(5): 701-704, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984826
14.
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients.
Ann Hematol
; 97(11): 2205-2215, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29987350
15.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222267
16.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol
; 92(10): 1037-1046, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28675513
17.
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.
Hematol Oncol
; 38(2): 204-206, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31985842
18.
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Ann Hematol
; 93(8): 1391-400, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24705888
19.
Presumptive pulmonary toxocariasis in a patient affected by acute myeloid leukemia and Hodgkin lymphoma: case report and review of the literature in immunocompromised hosts.
Infez Med
; 32(1): 103-112, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456027
20.
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Am J Hematol
; 88(10): 838-42, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23757199